

Multi-Product Medical Device Company

- Focus on high-margin and single-use products
- Interventional, surgical or acute care settings
- Diversified portfolio with five lead medical technologies

Favorable entry point into the stock (Nasdaq: PAVM, PAVMZ)

Company about to bring high-margin, clinically game-changing products to market

Strong IP Position: 72 patents and patent applications across 10 families

Financial Stability: Sufficient Cash (\$7.8 million pro-forma cash as of 3/31/19) to achieve significant value-inflection milestones

Capital Structure: Approx. 32.1 million shares of common stock outstanding as of 5/21/19 (not including approx. 29.1 million convertible securities at weighted average price of \$1.84)

Significant Opportunities to Drive Future Profitable Growth with a Diversified Portfolio

CarpX – Large market (600,000 patients undergo traditional invasive surgery in US each year); high-margin, near-market ready; technology promises to improve recovery time for carpal tunnel patients (prolonged recovery is primary reason that up to 1.5 million patients in US continue to suffer in silence); number one contributor to workman’s compensation in US; patent claims allowed—awaiting issuance; reimbursed under existing surgical codes; small clinical safety study (~20 patients, 90-day follow-up, first nine patients successfully treated) to support FDA 510k clearance; safety and effectiveness documented in >100 cadavers.

EsoGuard and EsoCheck – Revolutionary, highly accurate Esophageal DNA Test (EsoGuard) and non-invasive Cell Collection Device (EsoCheck). Highlighted in the NCI’s [2020 Annual Plan and Budget Proposal](#) to Congress. Simple five-minute, office-based procedure to detect Barrett’s Esophagus (BE), precursor to deadly esophageal cancer, in 20 million US patients with chronic heart burn or acid reflux (GERD). Potential to save many lives through the early detection of BE. Over \$2 billion immediately addressable US market opportunity based on existing BE screening guidelines and 10% market penetration. Data on over 500 patients from completed and ongoing NIH-funded studies.


Product Selection – Critical Success Factors

Commercial opportunity must be an attractive market satisfying an unmet clinical need with a clear regulatory and insurance reimbursement pathway along with sufficient technologic complexity for patent protection and low enough cost of goods to properly support market outreach.

Management Team

Seasoned, highly skilled, strong track record of success, deep professional network aligned toward preferential access to developing breakthrough medical technologies. Expertise in direct-to-consumer (DTC), physician and professional market development and adoption toward standard of care.

Product Pipeline



	CarpX Minimally Invasive Device to Treat Carpal Tunnel Syndrome	EsoCheck/EsoGuard Non-Invasive Device & DNA Biomarkers to Detect Esophageal Cancer Precursor	PortIO Implantable Intraosseous Vascular Access Device	DisappEAR Antimicrobial Resorbable Ear Tubes	NextFlo Highly Accurate Disposable Infusion System
ESTIMATED MARKET SIZE	>\$1B	>\$2B	>\$750M	~\$300M	>\$1B
US REGULATORY PATH	510(k)	EsoCheck: 510(k) EsoGuard LDT: None EsoGuard IVD: PMA or <i>de novo</i>	<i>de novo</i>	510(k)	Class I
CURRENT STATUS	<ul style="list-style-type: none"> First-in-human (FIH) clinical safety study being conducted in New Zealand (~20 patients, 90-day follow-up) First nine patients successfully treated in FIH safety study 	<ul style="list-style-type: none"> Received EsoCheck FDA substantial equivalence opinion with 510(k) clearance imminent Have submitted for CPT billing code through AMA's PLA process for EsoGuard LDT 	<ul style="list-style-type: none"> Completed 7-day GLP animal study along with supplemental cadaver and acute animal studies Pilot animal study demonstrated maintenance-free implant duration of 62 days 	<ul style="list-style-type: none"> Completed 90-day animal study with excellent results including zero incidence of otorrhea 	<ul style="list-style-type: none"> Demonstrated constant flow rates across a wide range of IV bag heights with accuracy rates comparable to electronic infusion pumps
POTENTIAL UPCOMING MILESTONES	<ul style="list-style-type: none"> Completion of FIH clinical safety study FDA 510(k) resubmission and clearance CE Mark submission 	<ul style="list-style-type: none"> EsoCheck FDA 510(k) clearance Secure CPT billing code for EsoGuard LDT FDA pre-submission filing and in-person meeting for clinical trials supporting EsoGuard IVD widespread BE screening indication 	<ul style="list-style-type: none"> Conduct 90-day FIH clinical trial in dialysis patients in Columbia CE Mark submission Strategic partnership or sale FDA pre-submission meeting to define likely small human safety study 	<ul style="list-style-type: none"> FDA 510(k) submission 	<ul style="list-style-type: none"> Commercial launch Formal M&A process for strategic partnership or sale

Management Team



LISHAN AKLOG, MD
Chairman & CEO



DENNIS MCGRATH
President & CFO



BRIAN DEGUZMAN, MD
Chief Medical Officer



SHAUN O'NEIL
Chief Commercial Officer



RICH YAZBECK
Chief Technology Officer

